Bibliographic Details
| Title: |
Clinically conserved genomic subtypes of gastric adenocarcinoma. |
| Authors: |
Jeong, Yun Seong, Eun, Young-Gyu, Lee, Sung Hwan, Kang, Sang-Hee, Yim, Sun Young, Kim, Eui Hyun, Noh, Joo Kyung, Sohn, Bo Hwa, Woo, Seon Rang, Kong, Moonkyoo, Nam, Deok Hwa, Jang, Hee-Jin, Lee, Hyun-Sung, Song, Shumei, Oh, Sang Cheul, Lee, Jeeyun, Ajani, Jaffer A., Lee, Ju-Seog |
| Source: |
Molecular Cancer; 9/6/2023, Vol. 22 Issue 1, p1-17, 17p |
| Subject Terms: |
GENE expression, GENOMICS, ADENOCARCINOMA, INVESTIGATIONAL therapies, RADIOTHERAPY |
| Abstract: |
Gastric adenocarcinoma (GAC) is a lethal disease characterized by genomic and clinical heterogeneity. By integrating 8 previously established genomic signatures for GAC subtypes, we identified 6 clinically and molecularly distinct genomic consensus subtypes (CGSs). CGS1 have the poorest prognosis, very high stem cell characteristics, and high IGF1 expression, but low genomic alterations. CGS2 is enriched with canonical epithelial gene expression. CGS3 and CGS4 have high copy number alterations and low immune reactivity. However, CGS3 and CGS4 differ in that CGS3 has high HER2 activation, while CGS4 has high SALL4 and KRAS activation. CGS5 has the high mutation burden and moderately high immune reactivity that are characteristic of microsatellite instable tumors. Most CGS6 tumors are positive for Epstein Barr virus and show extremely high levels of methylation and high immune reactivity. In a systematic analysis of genomic and proteomic data, we estimated the potential response rate of each consensus subtype to standard and experimental treatments such as radiation therapy, targeted therapy, and immunotherapy. Interestingly, CGS3 was significantly associated with a benefit from chemoradiation therapy owing to its high basal level of ferroptosis. In addition, we also identified potential therapeutic targets for each consensus subtype. Thus, the consensus subtypes produced a robust classification and provide for additional characterizations for subtype-based customized interventions. [ABSTRACT FROM AUTHOR] |
|
Copyright of Molecular Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
